{"id":"risedronate-hmr4003","safety":{"commonSideEffects":[{"rate":"5–15","effect":"Gastrointestinal irritation (esophageal irritation, dyspepsia, abdominal pain)"},{"rate":"5–10","effect":"Musculoskeletal pain (bone, joint, muscle pain)"},{"rate":"3–5","effect":"Headache"},{"rate":"2–5","effect":"Diarrhea"},{"rate":"<1","effect":"Atypical femoral fracture (rare)"},{"rate":"<1","effect":"Osteonecrosis of the jaw (rare)"}]},"_chembl":{"chemblId":"CHEMBL1654","moleculeType":"Small molecule","molecularWeight":"305.10"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risedronate is a bisphosphonate that localizes to sites of bone resorption and directly inhibits osteoclast function, reducing bone turnover. By suppressing osteoclast-mediated bone resorption, it increases bone mineral density and reduces fracture risk in conditions characterized by accelerated bone loss.","oneSentence":"Risedronate inhibits bone resorption by binding to hydroxyapatite on bone surfaces and inhibiting osteoclast activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:16.550Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Osteoporosis in men"},{"name":"Paget's disease of bone"},{"name":"Glucocorticoid-induced osteoporosis"}]},"trialDetails":[{"nctId":"NCT00353080","phase":"PHASE3","title":"Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-12","conditions":"Osteoporosis, Postmenopausal","enrollment":171},{"nctId":"NCT00358176","phase":"PHASE3","title":"Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Osteoporosis Postmenopausal","enrollment":1231},{"nctId":"NCT00402441","phase":"PHASE4","title":"Risedronate in the Prevention of Osteoporosis in Postmenopausal Women","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-09","conditions":"Osteoporosis, Postmenopausal","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Risedronate (HMR4003)","genericName":"Risedronate (HMR4003)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risedronate inhibits bone resorption by binding to hydroxyapatite on bone surfaces and inhibiting osteoclast activity. Used for Osteoporosis in postmenopausal women, Osteoporosis in men, Paget's disease of bone.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}